Velpatasvir — fast facts and what you need to know
Velpatasvir is an antiviral drug used to treat hepatitis C virus (HCV). You’ll most often see it combined with sofosbuvir in a single pill (brand name Epclusa). That combo works across all common HCV genotypes and is given as a short daily course to clear the virus and stop liver damage.
How velpatasvir works and typical dosing
Velpatasvir blocks the virus protein called NS5A, which the virus needs to copy itself. When paired with sofosbuvir, the two drugs attack HCV at different steps. The usual dose is one tablet once a day for 12 weeks for most patients. Some people with advanced liver disease may need a different plan—your doctor will decide.
What to expect: side effects and safety tips
Common side effects are mild: headache, tiredness, and nausea. Serious reactions are rare, but hepatitis B can flare up if you have a hidden infection—so clinicians test for HBV before starting treatment. Tell your provider about all medicines you take. Some drugs reduce velpatasvir levels or raise their side effects.
Key interaction tips: avoid St. John’s wort and rifampin. Acid-reducing drugs change how velpatasvir absorbs: take antacids several hours apart, and discuss PPI/H2 blocker use with your doctor. Certain statins and anticonvulsants can also interact—always check with a pharmacist.
Keep to the same time each day, with or without food unless told otherwise. Finish the full course; stopping early lowers the chance of clearing the virus. Store at room temperature away from strong light.
Before treatment starts you should have blood tests (HCV RNA, liver tests) and possibly an ultrasound or fibrosis assessment. After treatment, doctors usually check HCV RNA at 12 weeks to confirm sustained virologic response (SVR), which is the goal.
Access and cost: Epclusa is a branded option in many countries, but generic versions exist in some places and through licensed programs. If you’re considering buying online, use only reputable pharmacies and confirm prescriptions and licensing—fake or substandard meds are a real risk.
Pregnancy and breastfeeding: evidence is limited. If you’re pregnant or planning pregnancy, discuss timing with your doctor. Also talk about alcohol use and other liver risks—reducing those helps the liver recover faster.
Quick checklist before starting velpatasvir:
- Test for hepatitis B and other liver conditions.
- Review all medicines and supplements for interactions.
- Plan for baseline and post-treatment HCV RNA testing.
- Ask about cost, generic options, and safe pharmacy sources.
If you want specific dosing changes, interaction checks, or help finding treatment programs, your healthcare provider or pharmacist can give tailored advice. Velpatasvir has changed HCV care for many people—used correctly, it’s a powerful option.
Jul, 12 2023